1. Home
  2. XYF vs TNYA Comparison

XYF vs TNYA Comparison

Compare XYF & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XYF

X Financial each representing six

HOLD

Current Price

$4.89

Market Cap

186.4M

Sector

Finance

ML Signal

HOLD

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

171.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
TNYA
Founded
2014
2016
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.4M
171.4M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
XYF
TNYA
Price
$4.89
$0.79
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.33
AVG Volume (30 Days)
133.3K
4.7M
Earning Date
05-18-2026
05-07-2026
Dividend Yield
11.34%
N/A
EPS Growth
N/A
54.96
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$0.43
52 Week High
$20.36
$2.35

Technical Indicators

Market Signals
Indicator
XYF
TNYA
Relative Strength Index (RSI) 53.62 48.89
Support Level $4.86 $0.65
Resistance Level $5.12 $0.82
Average True Range (ATR) 0.31 0.08
MACD -0.02 -0.01
Stochastic Oscillator 67.33 11.57

Price Performance

Historical Comparison
XYF
TNYA

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Share on Social Networks: